BioCentury | Apr 14, 2020
Deals

Expanded deal with Kyowa could give MEI cash through drug approval

...clinical assets include CDK4/CDK6 inhibitor voruciclib, for B cell malignancies and AML; and mitochondrial inhibitor ME-344...
BioCentury | Jun 15, 2018
Clinical News

MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

...MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of tumor cell...
...Oncologicas. ME-344 is an isoflavone-derived mitochondrial inhibitor. MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Product: ME-344...
...by reductions in antigen KI-67 (MKI67; Ki-67) expression Status: Phase 0 data Milestone: NA Allison Johnson ME-344, nv-344 American...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Ib trial of ME-401. It also presented interim clinical data from an investigator-initiated study of ME-344...
BioCentury | Oct 17, 2016
Finance

Helsinn looks upstream

...including two Phase I cancer programs: ME-401 , a phosphoinositide 3-kinase (PI3K) delta inhibitor; and ME-344...
BioCentury | Jul 14, 2016
Distillery Therapeutics

Therapeutics: Multiple kinase targets; an undisclosed target

...Cancer INDICATION: Cancer; breast cancer; lung cancer Mouse studies suggest the mitochondrial inhibitor ME-344 and/or the...
...Stivarga regorafenib-resistant metastatic breast cancer and a patient-derived xenograft mouse model of Stivarga-resistant lung cancer, ME-344...
...compared with any of the agents alone. In a mouse model of Stivarga-resistant lung carcinoma, ME-344...
BioCentury | May 12, 2014
Clinical News

ME-344: Phase Ib started

...MEI began a 2-part, open-label, U.S. Phase Ib trial to evaluate IV ME-344 in combination with...
...with solid tumors. In the first part, up to 24 patients will receive 10 mg/kg ME-344...
...NYSE:GSK, London, U.K.) markets Hycamtin. MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Product: ME-344 (formerly NV-344...
BioCentury | Oct 28, 2013
Clinical News

ME-344: Phase I data

...trial showed that 5 of 21 evaluable patients with refractory solid tumors who received IV ME-344...
...with a 32% reduction in target lesions. Additionally, there were 7 cases of stable disease. ME-344...
...see BioCentury, Nov. 19, 2012). MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Product: ME-344 (formerly NV-344...
BioCentury | Nov 19, 2012
Company News

Ligand, MEI Pharma deal

...rights to MEI to use Captisol modified beta-cyclodextrin reformulation technology in MEI's lead isoflavone-based compounds, ME-344...
...ME-344 is a mitochondrial inhibitor and an active metabolite of NV-128 , a first-generation compound. ME-344...
BioCentury | Jun 4, 2012
Clinical News

ME-344: Phase I started

...U.S. Phase I trial to evaluate once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344...
...to 24 patients. Patients will then be eligible to receive the maximum tolerated dose of ME-344...
...15 and 16 of a 28-day cycle. Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif. Product: ME-344...
BioCentury | Apr 16, 2012
Clinical News

ME-344: Phase I start

...IV ME-344 in up to 24 patients. Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif. Product: ME-344...
Items per page:
1 - 10 of 10